Data edition of
Residue An evidence-graded reference for peptide science

Retatrutide clinical trials

Every study registered on ClinicalTrials.gov that lists Retatrutide as an intervention, as of the data edition — what is being tested, in whom, by whom, and how far it has got.

Registered studies
34
Active or recruiting
11
Completed
22
With posted results
2
Planned or actual enrollment
27,231participants, summed
Registered studies of Retatrutide by phase and status
PhaseStudiesBreakdown
Phase 1 15
14 completed, 1 active or recruiting, 0 stopped, 0 other
Phase 2 4
3 completed, 1 active or recruiting, 0 stopped, 0 other
Phase 3 14
5 completed, 9 active or recruiting, 0 stopped, 0 other
Expanded access 1
0 completed, 0 active or recruiting, 0 stopped, 1 other
Figure 1. 34 studies on ClinicalTrials.gov match the registry search retatrutide OR LY3437943. Multi-phase studies are counted at their highest phase. Open the full trial feed

Conditions studied

  1. Obesity15
  2. Overweight9
  3. Healthy7
  4. Type 2 Diabetes4
  5. Diabetes Mellitus, Type 23
  6. Obstructive Sleep Apnea2
  7. Overweight or Obesity1
  8. CKD1
  9. Metabolic Dysfunction-Associated Steatotic Liver Disease1
  10. Chronic Low Back Pain (CLBP)1
  11. Atherosclerotic Cardiovascular Disease (ASCVD)1
  12. Chronic Kidney Disease (CKD)1

Lead sponsors

  1. Eli Lilly and Company33
  2. Hudson Biotech1

The registry, study by study

Registration is not evidence of benefit; many registered studies never publish. Status and dates are as reported by sponsors to ClinicalTrials.gov.

Status
Phase

34 shown

Registered studies of Retatrutide
StudyPhaseStatusStartnSponsor
NCT07467447Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight Phase 2 Recruiting Feb 2026 300 Hudson Biotech
NCT07357415A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight Phase 3 Active, not recruiting Jan 2026 600 Eli Lilly and Company
NCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight Phase 3 Active, not recruiting Nov 2025 250 Eli Lilly and Company
NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Phase 3 Recruiting Oct 2025 4,500 Eli Lilly and Company
NCT06982859A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Phase 1 Active, not recruiting Jun 2025 95 Eli Lilly and Company
NCT07035093A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain Phase 3 Active, not recruiting May 2025 586 Eli Lilly and Company
NCT06859268A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Phase 3 Active, not recruiting Mar 2025 643 Eli Lilly and Company
NCT06662383A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Phase 3 Active, not recruiting Nov 2024 800 Eli Lilly and Company
NCT06383390The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Phase 3 Active, not recruiting Apr 2024 10,000 Eli Lilly and Company
NCT06297603Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Phase 3 Active, not recruiting Mar 2024 320 Eli Lilly and Company
NCT06260722Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Phase 3 Active, not recruiting Feb 2024 1,250 Eli Lilly and Company
NCT06982846A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia Phase 1 Completed Jun 2025 80 Eli Lilly and Company
NCT06808802To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants Phase 1 Completed Feb 2025 30 Eli Lilly and Company
NCT06354660Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Phase 3 Completed Apr 2024 537 Eli Lilly and Company
NCT06313528A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 Phase 1 Completed Mar 2024 85 Eli Lilly and Company
NCT06039826A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese Phase 1 Completed Sep 2023 46 Eli Lilly and Company
NCT06003465A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices Phase 1 Completed Aug 2023 57 Eli Lilly and Company
NCT05931367A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Phase 3 Completed Aug 2023 445 Eli Lilly and Company
NCT05936151A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Phase 2 Completed Jul 2023 146 Eli Lilly and Company
NCT05959096A Study of LY3437943 in Healthy Participants With a High Body Mass Index Phase 1 Completed Jul 2023 85 Eli Lilly and Company
NCT05916560A Study of LY3437943 in Participants With Impaired and Normal Liver Function Phase 1 Completed Jul 2023 43 Eli Lilly and Company
NCT05929079A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight Phase 3 Completed Jul 2023 1,152 Eli Lilly and Company
NCT05929066A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight Phase 3 Completed Jul 2023 2,335 Eli Lilly and Company
NCT05882045A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease Phase 3 Completed May 2023 1,946 Eli Lilly and Company
NCT05757531A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants Phase 1 Completed Mar 2023 7 Eli Lilly and Company
NCT05611957A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function Phase 1 Completed Nov 2022 29 Eli Lilly and Company
NCT05548231A Study of LY3437943 in Chinese Participants With Obesity Or Overweight Phase 1 Completed Oct 2022 32 Eli Lilly and Company
NCT05445232A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants Phase 1 Completed Jul 2022 32 Eli Lilly and Company
NCT04823208A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) Phase 1 Completed May 2021 64 Eli Lilly and Company
NCT04881760A Study of LY3437943 in Participants Who Have Obesity or Are OverweightResults posted Phase 2 Completed May 2021 338 Eli Lilly and Company
NCT04867785A Study of LY3437943 in Participants With Type 2 DiabetesResults posted Phase 2 Completed May 2021 281 Eli Lilly and Company
NCT04143802A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) Phase 1 Completed Dec 2019 72 Eli Lilly and Company
NCT03841630A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants Phase 1 Completed Mar 2019 45 Eli Lilly and Company
NCT07629401Pre-approval Expanded Access of Retatrutide (LY3437943) Expanded access Available — — Eli Lilly and Company

Run this search on ClinicalTrials.gov → Query term: retatrutide OR LY3437943